(March 7, 2017, 1:52 PM EST) -- BOSTON — A Massachusetts federal judge’s decision to dismiss allegations that Momenta Pharmaceuticals Inc. made knowing misrepresentations to the U.S. Pharmacopeial Convention (USP) — the standard-setting organization (SSO) charged with ensuring the quality control of drugs — was reversed March 6 by the First Circuit U.S. Court of Appeals (Amphastar Pharmaceuticals Inc. v. Momenta Pharmaceuticals Inc., et al., No. 16-2113, 1st Cir., 2017 U.S. App. LEXIS 3956)....